chenguang biotech group (300138.SZ): Currently no fertilizer business

Glonghui reported on November 28 that chenguang biotech group (300138.SZ) stated on the investor interaction platform that the company currently has no business in fertilizers. The byproducts such as residue from the production processes of the company's lutein and stevia products can be used as raw materials for downstream fertilizer companies.

Gelonghui FinanceNov 28 02:09 ET

chenguang biotech group (300138.SZ): The main sugar substitute product is stevia sugar, with a current production capacity of 2000 tons per year.

Gelonghui November 11th | Chenguang Biotech Group (300138.SZ) stated on the investor interaction platform that the company's sugar substitute products are mainly stevia sugar, with a current production capacity of 2000 tons/year. The products have a production cost advantage and yield is in a leading position in the industry.

Gelonghui FinanceNov 11 03:49 ET

Chenguang Biology: Report for the third quarter of 2024

SZSIOct 25 12:00 ET · Announcements

Chenguang Biotech Group (300138.SZ) released its performance for the first three quarters, with a net income of 62.6059 million yuan, a decrease of 84.28%.

Chenguang Biotech Group (300138.SZ) released the third quarter report of 2024, with the company's revenue for the first three quarters at 5...

Zhitong FinanceOct 25 07:59 ET

Is ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) 8.1% ROE Better Than Average?

Simply Wall StOct 23 20:14 ET

Chenguang Biotech Group (300138.SZ): has completed the record filing of Motherwort Formula Granules and Salvia Formula Granules, and actively carried out market development.

Guolonghui Oct. 16th | Chenguang Biotech Group (300138.SZ) stated at an investor relations event that its subsidiary Chenguang Pharmaceutical has completed the record filing of Motherwort Formula Granules and Salvia Miltiorrhiza Formula Granules and is actively exploring the market. Currently, the business is still in the early stage of layout. At this stage, the traditional chinese medicine formula granule market is still dominated by multi-variety enterprises, but models with a small number of varieties, refined management, and large-scale production can significantly improve industry efficiency, reduce waste of resources in various aspects of the industry chain, and better leverage the company's strengths. The company will continue to explore this model.

Gelonghui FinanceOct 16 03:29 ET